- Home
- CLRB vs RMCO Comparison
CLRB vs RMCO Comparison
Compare CLRB & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- RMCO
- Stock Information
- Founded
- CLRB 2002
- RMCO 2021
- Country
- CLRB United States
- RMCO United States
- Employees
- CLRB N/A
- RMCO N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- RMCO Multi-Sector Companies
- Sector
- CLRB Health Care
- RMCO Miscellaneous
- Exchange
- CLRB Nasdaq
- RMCO Nasdaq
- Market Cap
- CLRB 15.3M
- RMCO 14.9M
- IPO Year
- CLRB N/A
- RMCO N/A
- Fundamental
- Price
- CLRB $0.31
- RMCO $1.10
- Analyst Decision
- CLRB Buy
- RMCO
- Analyst Count
- CLRB 2
- RMCO 0
- Target Price
- CLRB $28.00
- RMCO N/A
- AVG Volume (30 Days)
- CLRB 1.4M
- RMCO 9.5K
- Earning Date
- CLRB 03-26-2025
- RMCO 03-07-2025
- Dividend Yield
- CLRB N/A
- RMCO N/A
- EPS Growth
- CLRB N/A
- RMCO N/A
- EPS
- CLRB N/A
- RMCO N/A
- Revenue
- CLRB N/A
- RMCO $695,792.00
- Revenue This Year
- CLRB N/A
- RMCO N/A
- Revenue Next Year
- CLRB N/A
- RMCO N/A
- P/E Ratio
- CLRB N/A
- RMCO N/A
- Revenue Growth
- CLRB N/A
- RMCO 46.15
- 52 Week Low
- CLRB $0.22
- RMCO $0.70
- 52 Week High
- CLRB $4.45
- RMCO $1.80
- Technical
- Relative Strength Index (RSI)
- CLRB 46.10
- RMCO 47.96
- Support Level
- CLRB $0.26
- RMCO $1.07
- Resistance Level
- CLRB $0.35
- RMCO $1.14
- Average True Range (ATR)
- CLRB 0.03
- RMCO 0.06
- MACD
- CLRB 0.02
- RMCO -0.01
- Stochastic Oscillator
- CLRB 61.40
- RMCO 17.54
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.